The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).
 
Lori J. Wirth
Consulting or Advisory Role - Amgen; Ayala Pharmaceuticals; Blueprint Medicines; CUE Biopharma; Eisai; Loxo; Merck; Novartis
Other Relationship - Iovance Biotherapeutics
 
Sophie Leboulleux
Research Funding - Novartis; Sanofi (Inst)
 
Naomi Kiyota
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Eisai; Merck Serono; Ono Pharmaceutical
Speakers' Bureau - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Eisai; Merck Serono; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst)
 
Makoto Tahara
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Merck Serono; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Amgen; Aspyrian Therapeutics; Bristol-Myers Squibb; Celgene; MSD; Ono Pharmaceutical; Pfizer
Research Funding - Aspyrian Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Kei Muro
Honoraria - Bayer; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst)
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; MSD
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; MSD
 
Yuichi Ando
Honoraria - AstraZeneca; Bayer Holding; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Merck Serono; Mochida Pharmaceutical Co. Ltd.; Nippon Kayaku; Novartis; Novartis; Ono Pharmaceutical; Sawai Pharmaceutical Co; Shionogi; Taiho Pharmaceutical; Tsumura & Co.; Yakult Honsha
Consulting or Advisory Role - ICON Clinical Research; Kowa; Ono Pharmaceutical; SymBio Pharmaceuticals
Research Funding - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Mochida Pharmaceutical Co. Ltd.; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Matthew H. Taylor
Consulting or Advisory Role - ArQule; Array BioPharma; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Eisai; Loxo; Novartis
Speakers' Bureau - Bristol-Myers Squibb; Eisai
 
Shunji Takahashi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Novartis
 
Sung-Bae Kim
Consulting or Advisory Role - Enzychem Lifesciences (Inst); Lilly (Inst); Novartis (Inst); Odonate Therapeutics (Inst)
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Novartis (Inst)
 
Soamnauth Misir
Employment - Eisai
 
Corina E. Dutcus
Employment - Eisai
Leadership - Eisai
Research Funding - Eisai (Inst)
 
Ran Xie
Employment - Eisai
 
Prashant Ramesh Joshi
Employment - Eisai
 
Brett Gordon Maxwell Hughes
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; MSD Oncology; Pfizer; Roche
Research Funding - Amgen (Inst)
 
Javier Aller
Consulting or Advisory Role - Bayer; Eisai; Ipsen; Novartis; Sanofi
Speakers' Bureau - Bayer; Eisai; Ipsen; Novartis; Sanofi
Research Funding - Eisai; Ipsen
Travel, Accommodations, Expenses - Ipsen; Novartis
 
Monika K. Krzyzanowska
Honoraria - Eisai; Novartis
Consulting or Advisory Role - Eisai
Research Funding - Eisai (Inst); Exelixis (Inst); Ipsen (Inst)
 
Jaume Capdevila
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Eisai; Exelixis; Ipsen; Merck Serono; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Eisai; Ipsen; Merck Serono; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Ipsen (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Eisai; Ipsen; Pfizer